NDAORALCAPSULEPriority Review
Approved
May 1985
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RIDAURA (auranofin) is an oral gold compound approved in 1985 for rheumatoid arthritis and indicated for parasitic infections including amoebiasis and giardiasis. The mechanism of action involves gold's anti-inflammatory and immunomodulatory properties, though the exact pharmacologic class is not fully specified in modern literature. It represents an older generation of RA therapy now largely superseded by JAK inhibitors and TNF blockers.
$0.994MPart D
LOE ApproachingDeclining
<1% of rheumatoid arthritis market
Minimal commercial infrastructure; shrinking patient base and limited growth opportunities suggest small, maintenance-focused team with likely consolidation or divestment risk.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Auranofin for Giardia Protozoa
Started Nov 2016
93 enrolled
Amoebic DysenteryGiardiasis
Auranofin PK Following Oral Dose Administration
Started Apr 2014
15 enrolled
Amoebiasis
Career Relevance
Working on RIDAURA offers minimal career upside; the product lacks linked job postings and operates as a legacy asset with declining utilization and no growth initiatives. Career value lies only in niche medical affairs roles focused on existing patient populations rather than expansion or launch activities.
Company
Worked on RIDAURA at Enterprise Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.